S&P Futures
3,776.75 -44.50 (-1.16%) Dow Futures
30,707.00 -292.00 (-0.94%) Nasdaq Futures
11,526.50 -164.50 (-1.41%) Russell 2000 Futures
1,699.70 -21.70 (-1.26%) Crude Oil
109.93 +0.15 (+0.14%) Gold
1,815.60 -1.90 (-0.10%)
Neoleukin Therapeutics, Inc. (NLTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.0400 |
| Open | 1.0500 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 900 |
| Day's Range | 0.9800 - 1.0700 |
| 52 Week Range | 0.7950 - 9.7500 |
| Volume | |
| Avg. Volume | 380,535 |
| Market Cap | 43.277M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0590 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.71 |
- GlobeNewswire
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory soli
- GlobeNewswire
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. “During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escala
- GlobeNewswire
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in two upcoming investor conferences. Presentation details are as follows: BofA Securities 2022 Healthcare Conference – Las Vegas, NV Fireside chatWednesday May 11, 2022, at 1:20 p.m. Pacific H.C. Wa
